Connect Biopharma Holdings (CNTB) Research & Development (2024 - 2026)

Connect Biopharma Holdings has disclosed Research & Development across 3 years of filings, most recently posting $16.3 million for Q2 2026.

• In Q2 2026, Research & Development rose 85.49% year-over-year to $16.3 million; the TTM figure through Jun 2026 stood at $53.7 million (up 75.18% YoY), while the FY2025 annual figure was $37.8 million, up 29.2% from the prior year.
• Research & Development came in at $16.3 million for Q2 2026 at Connect Biopharma Holdings, up from $15.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $16.3 million in Q2 2026 to a low of $5.3 million in Q2 2024.
• Average Research & Development over 3 years is $9.8 million, with a median of $8.9 million recorded in 2024.
• Year-over-year, Research & Development decreased 23.43% in 2025 and jumped 126.59% in 2026.
• Over 3 years, Research & Development stood at $6.2 million in 2024, then jumped by 80.92% to $11.3 million in 2025, then surged by 44.24% to $16.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $16.3 million in Q2 2026, $15.0 million in Q1 2026, and $11.3 million in Q4 2025.